Posted by Michael Wonder on 11 Oct 2018
New value assessment framework needed for biosimilars, white paper argues
11 October 2018 - As US healthcare increasingly moves toward value-based payment approaches, biosimilars, which reduce costs while maintaining treatment quality, can be an important driver of value. However, according to a white paper, a new framework for assessing the value of biosimilars is warranted.
In response to rising healthcare costs, a variety of value assessment frameworks have been developed, including the American Society of Clinical Oncology Value Framework, the Memorial Sloan Kettering Cancer Center’s DrugAbacus, the National Comprehensive Cancer Network’s Evidence Blocks, and the Avalere–Faster Cures Patient-Perspective Value Framework, along with reviews undertaken by the Institute for Clinical and Economic Review.
However, the white paper argues that no current value assessment framework is fully suited to assessing the value of biosimilar medicines; several of the above frameworks focus on oncology drugs alone, ICER’s focus on QALYs has been questioned for its appropriateness, and each framework is oriented to the perspective of a particular stakeholder.
